+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The Value of Monitoring the Serum Concentration of Mycophenolate Mofetil in Children with Steroid-Dependent/Frequent Relapsing Nephrotic Syndrome

The Value of Monitoring the Serum Concentration of Mycophenolate Mofetil in Children with Steroid-Dependent/Frequent Relapsing Nephrotic Syndrome

Nephron 132(4): 327-334

Mycophenolate mofetil (MMF) is an alternative treatment strategy in children with steroid sensitivity who have frequent relapses or steroid-dependent nephrotic syndrome (FRNS/SDNS). From January 2009 to January 2015, 31 cases of children with FRNS/SDNS were prospectively recruited and administered MMF and prednisone; then, serum samples were collected, and the area under the curve (AUC) of mycophenolic acid (MPA-AUC) was calculated. A MPA-AUC of 27.99 μg·h/ml had a diagnostic sensitivity of 65.2% and a specificity of 87.5% in discriminating relapsing from non-relapsing patients (receiver operating characteristic-AUC 0.848). The 31 patients were then grouped according to the results of the MPA-AUC as follows: low-AUC group, <30 μg·h/ml and high-AUC group, ≥30 μg·h/ml. The results indicated that there was a significant difference in the remission rate between the groups (x03C7;2 = 6.645, p = 0.01) during the 6 months of follow-up. Compared with the results before MMF therapy, the steroid dosage in both groups was significantly reduced at the 6- and 12-month follow-ups. Furthermore, the steroid dose was reduced more significantly in the high-AUC group than in the low-AUC group (0.447 ± 0.254 vs. 0.219 ± 0.161 mg/kg/day, p = 0.006) at the 6-month follow-up. Compared with the low-AUC group at the 6-month follow-up, the number of patients with relapse and relapse episodes in the high-AUC group were also significantly reduced (7/16 vs. 1/15, p = 0.037, and 15/27 vs. 1/29, p = 0.014, respectively). MMF is a reasonable treatment choice to reduce the number of relapse episodes and steroid administration in children with FRNS/SDNS. Moreover, children in the high-AUC group (MPA-AUC ≥30 μg·h/ml) tended to require lower steroid doses and had greater remission rates than the patients in the low-AUC group (<30 μg·h/ml) at the 6-month follow-up.

(PDF emailed within 0-6 h: $19.90)

Accession: 059036895

Download citation: RISBibTeXText

PMID: 26991496

DOI: 10.1159/000445070

Related references

Multicenter trial of mycophenolate mofetil in children with steroid dependent or frequent relapsing nephrotic syndrome Report of the Southwest Pediatric Nephrology Study Group. Journal of the American Society of Nephrology 14(Abstracts Issue): 751A, November, 2003

Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome. Annals of Saudi Medicine 25(5): 380-384, 2005

Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome. Nephrology 21(1): 21-27, 2016

Mycophenolate mofetil and cyclosporine in the treatment of steroid-dependent nephrotic syndrome with frequent relapses. Anales de Pediatria 69(3): 258-262, 2008

Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions. Pediatric Nephrology 20(10): 1376-1381, 2005

Should mycophenolate mofetil be administered prior to cyclosporine A as a steroid-sparing agent to children with steroid-dependent nephrotic syndrome?. Pediatric Nephrology: -, 2018

Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. American Journal of Kidney Diseases 42(6): 1114-1120, 2003

Mycophenolate Sodium for Children with Frequently Relapsing or Steroid Dependent Nephrotic Syndrome. Indian Pediatrics 54(10): 885-886, 2018

Mycophenolate mofetil treatment in steroid resistant/relapsing nephrotic syndrome of childhood. Journal of the American Society of Nephrology 10(PROGRAM AND ABSTR ISSUE): 111A, Sept, 1999

Mycophenolate mofetil (MMF) as the first choice immunosuppressive drug in treatment of steroid-dependent nephrotic syndrome in children. Polski Merkuriusz Lekarski 44(262): 192-195, 2018

Treatment of frequent relapsing, steroid-dependent and steroid-resistant minimal change nephrotic syndrome in 160 children. Pediatric Nephrology 13(7): C66, Sept, 1999

Predictors of frequent relapsing and steroid-dependent nephrotic syndrome in children. Turk Pediatri Arsivi 53(1): 24-30, 2018

Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome. Pediatric Nephrology 30(4): 687-691, 2015

Mycophenolate mofetil allows steroid withdrawal in steroid dependent nephrotic syndrome. Pediatric Research 51(4 Part 2): 429A, April, 2002

Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. Journal of the American Society of Nephrology 24(10): 1689-1697, 2013